NCT05042609 - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma | Biotech Hunter

Enrollment

142

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

June 29, 2023

Study Completion Date

June 29, 2023

Conditions

Non-infectious Anterior UveitisUveitic Glaucoma

Interventions

DRUG

TRS01

TRS01 eye drops Dosed four times a day (QID)

DRUG

FDA approved steroid eye drop (masked)

FDA approved steroid eye drop Dosed four times a day (QID)

Trial Locations (30)

21079

Dijon, Dijon

23502

Norfolk, Norfolk

27157

Winston-Salem, Winston-Salem

30060

Marietta, Marietta

32204

Jacksonville, Jacksonville

33800

Winter Haven, Winter Haven

37232

Nashville, Nashville

40225

Düsseldorf, Düsseldorf

44000

Nantes, Nantes

48145

Munster, Münster

53127

Bonn, Bonn

63090

Washington, MO, Washington

69004

Lyon, Lyon

72076

Tübingen, Tübingen

75013

Paris, Paris

75014

Paris, Paris

75075

Plano, Plano

78238

San Antonio 2, San Antonio

78240

San Antonio, San Antonio

78712

Austin, Austin

79106

Freiburg, Freiburg im Breisgau

80045

Aurora, Aurora

80228

Lakewood, Lakewood

80336

München, München

90041

Los Angeles, Los Angeles

92093

La Jolla, La Jolla

90095-6984

Los Angeles 2, Los Angeles

02114

Boston, Boston

02451

Waltham, Waltham

07650

Palisades Park, Palisades Park